Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AEG35156 + gemcitabine
- Development stage
- Unknown
- Lead developer
- Pharmascience
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
AEG35156 + gemcitabine is a drug combination consisting of an **antisense oligonucleotide (AEG35156)** targeting the X-linked inhibitor of apoptosis protein (XIAP) mRNA, and **gemcitabine**, a nucleoside analog antimetabolite used as chemotherapy. AEG35156 reduces XIAP expression, thereby promoting apoptosis and potentially sensitizing cancer cells to chemotherapy. Preclinical studies demonstrated potent activity in pancreatic ductal adenocarcinoma (PDA). In a phase I clinical trial in metastatic PDA, the combination aimed to establish safety, maximum tolerated dose, and preliminary efficacy. The combination did not demonstrate significant antitumor activity in advanced PDA.
02
Targets
XIAPDNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on AEG35156 + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AEG35156 + gemcitabine.